Max Cotler
Chief Executive Officer GelMEDIX
Dr. Cotler is Chief Executive Officer of GelMEDIX after a series of increasing roles starting from the founding in 2020. Prior to GelMEDIX, he completed his PhD in Medical Engineering from MIT in the Harvard-MIT Program in Health Sciences and Technology with a research background in drug delivery systems and translational medicine. His research ranged from chronic brain implants for modulating highly specific neural circuits to utilizing machine learning to predict optimal cancer treatments utilizing a 24 hour micro-implant assay resulting numerous conference presentations and publications. Dr. Cotler was an MIT Presidential Fellow and NSF Graduate Research Fellow and holds a BS in Biomedical Engineering from Boston University.
Seminars
- Examine how injectable hydrogel scaffolds can protect therapeutic cells during administration, improve retention at the target site, and enhance long-term functional integration
- Understand the practical considerations involved in selecting surgical delivery devices, designing translational studies, and generating the evidence needed to support regulatory approval
- Explore how hydrogel platforms are being adapted for cell therapies, gene therapies, and other advanced modalities to improve efficacy, safety, and clinical adoption
